12/19
04:30 pm
gern
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Medium
Report
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
12/18
01:52 pm
gern
Geron Corporation (NASDAQ:GERN) is a favorite amongst institutional investors who own 72% [Yahoo! Finance]
Medium
Report
Geron Corporation (NASDAQ:GERN) is a favorite amongst institutional investors who own 72% [Yahoo! Finance]
12/18
09:13 am
gern
Headlamp Health Appoints Veteran Healthcare Technology Leader as Chief Executive Officer and Board Member [Yahoo! Finance]
Medium
Report
Headlamp Health Appoints Veteran Healthcare Technology Leader as Chief Executive Officer and Board Member [Yahoo! Finance]
12/13
09:29 am
gern
Geron Co. (NASDAQ: GERN) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $6.00 price target on the stock.
Low
Report
Geron Co. (NASDAQ: GERN) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $6.00 price target on the stock.
12/13
06:36 am
gern
Geron Announces Positive CHMP Opinion for RYTELO™ (imetelstat) for the Treatment of Adults with Transfusion-Dependent Anemia due to Lower-Risk MDS
Neutral
Report
Geron Announces Positive CHMP Opinion for RYTELO™ (imetelstat) for the Treatment of Adults with Transfusion-Dependent Anemia due to Lower-Risk MDS
12/10
09:32 am
gern
Geron Announces New IMerge Analyses Presented at ASH Suggesting Clinical Activity of RYTELO™ (imetelstat) in Patients with Lower-Risk MDS Regardless of Type or Number of Prior Therapies [Yahoo! Finance]
Low
Report
Geron Announces New IMerge Analyses Presented at ASH Suggesting Clinical Activity of RYTELO™ (imetelstat) in Patients with Lower-Risk MDS Regardless of Type or Number of Prior Therapies [Yahoo! Finance]
12/10
09:22 am
gern
Geron Announces Phase 1 Findings from Two-Part IMproveMF Study Presented at ASH Suggesting Tolerability of RYTELO™ (imetelstat) in Combination with Ruxolitinib as Frontline Therapy in Patients with Myelofibrosis [Yahoo! Finance]
Low
Report
Geron Announces Phase 1 Findings from Two-Part IMproveMF Study Presented at ASH Suggesting Tolerability of RYTELO™ (imetelstat) in Combination with Ruxolitinib as Frontline Therapy in Patients with Myelofibrosis [Yahoo! Finance]
12/10
09:00 am
gern
Geron Announces New IMerge Analyses Presented at ASH Suggesting Clinical Activity of RYTELO™ (imetelstat) in Patients with Lower-Risk MDS Regardless of Type or Number of Prior Therapies
Low
Report
Geron Announces New IMerge Analyses Presented at ASH Suggesting Clinical Activity of RYTELO™ (imetelstat) in Patients with Lower-Risk MDS Regardless of Type or Number of Prior Therapies
12/10
09:00 am
gern
Geron Announces Phase 1 Findings from Two-Part IMproveMF Study Presented at ASH Suggesting Tolerability of RYTELO™ (imetelstat) in Combination with Ruxolitinib as Frontline Therapy in Patients with Myelofibrosis
Low
Report
Geron Announces Phase 1 Findings from Two-Part IMproveMF Study Presented at ASH Suggesting Tolerability of RYTELO™ (imetelstat) in Combination with Ruxolitinib as Frontline Therapy in Patients with Myelofibrosis
12/10
08:00 am
gern
Geron Co. (NASDAQ: GERN) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $9.00 price target on the stock.
Low
Report
Geron Co. (NASDAQ: GERN) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $9.00 price target on the stock.
12/5
07:55 am
gern
Geron Co. (NASDAQ: GERN) was upgraded by analysts at Barclays PLC to a "strong-buy" rating.
Low
Report
Geron Co. (NASDAQ: GERN) was upgraded by analysts at Barclays PLC to a "strong-buy" rating.
11/27
09:05 am
gern
Geron to Participate in the 7th Annual Evercore ISI HealthCONx Conference [Yahoo! Finance]
Low
Report
Geron to Participate in the 7th Annual Evercore ISI HealthCONx Conference [Yahoo! Finance]
11/27
09:00 am
gern
Geron to Participate in the 7th Annual Evercore ISI HealthCONx Conference
Low
Report
Geron to Participate in the 7th Annual Evercore ISI HealthCONx Conference
11/22
07:28 am
gern
Geron Corp. (GERN): Among the NASDAQ Stocks with Biggest Upside Potential According to Analysts [Yahoo! Finance]
Low
Report
Geron Corp. (GERN): Among the NASDAQ Stocks with Biggest Upside Potential According to Analysts [Yahoo! Finance]
11/21
04:30 pm
gern
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
11/11
04:37 pm
gern
Geron Corporation Announces Appointment of Joseph Eid, M.D. as Executive Vice President, Research and Development [Yahoo! Finance]
Medium
Report
Geron Corporation Announces Appointment of Joseph Eid, M.D. as Executive Vice President, Research and Development [Yahoo! Finance]
11/11
04:30 pm
gern
Geron Corporation Announces Appointment of Joseph Eid, M.D. as Executive Vice President, Research and Development
Medium
Report
Geron Corporation Announces Appointment of Joseph Eid, M.D. as Executive Vice President, Research and Development
11/11
09:00 am
gern
Geron to Participate in the Stifel 2024 Healthcare Conference
Medium
Report
Geron to Participate in the Stifel 2024 Healthcare Conference
11/10
09:17 am
gern
Analysts Are Upgrading Geron Corporation (NASDAQ:GERN) After Its Latest Results [Yahoo! Finance]
Medium
Report
Analysts Are Upgrading Geron Corporation (NASDAQ:GERN) After Its Latest Results [Yahoo! Finance]
11/8
08:11 am
gern
Geron Corp (GERN) Q3 2024 Earnings Call Highlights: Strong Rytelo Launch and Strategic ... [Yahoo! Finance]
Low
Report
Geron Corp (GERN) Q3 2024 Earnings Call Highlights: Strong Rytelo Launch and Strategic ... [Yahoo! Finance]
11/7
04:47 pm
gern
Geron (GERN) Q3 2024 Earnings Call Transcript [Yahoo! Finance]
Low
Report
Geron (GERN) Q3 2024 Earnings Call Transcript [Yahoo! Finance]
11/7
07:18 am
gern
Geron Corporation Announces Up to $375 Million in Funding with Royalty Pharma and Pharmakon Advisors [Yahoo! Finance]
Low
Report
Geron Corporation Announces Up to $375 Million in Funding with Royalty Pharma and Pharmakon Advisors [Yahoo! Finance]
11/7
07:01 am
gern
Geron Corporation Announces Up to $375 Million in Funding with Royalty Pharma and Pharmakon Advisors
Low
Report
Geron Corporation Announces Up to $375 Million in Funding with Royalty Pharma and Pharmakon Advisors
11/7
07:00 am
gern
Geron Corporation Reports Third Quarter 2024 Financial Results and Recent Business Highlights
Low
Report
Geron Corporation Reports Third Quarter 2024 Financial Results and Recent Business Highlights
11/5
09:00 am
gern
Geron Announces New Data to be Presented at Upcoming ASH Annual Meeting Highlighting the Potential of RYTELO™ (imetelstat) in Myeloid Hematologic Malignancies
Low
Report
Geron Announces New Data to be Presented at Upcoming ASH Annual Meeting Highlighting the Potential of RYTELO™ (imetelstat) in Myeloid Hematologic Malignancies